Why Pediatric Lyme Treatment Needs Better Research

Major Lyme retreatment trials excluded children
Adult findings may not fully apply to pediatric patients
More research is needed for children with persistent symptoms

How strong is the evidence guiding pediatric Lyme treatment when symptoms continue after initial therapy? Published guidelines provide antibiotic recommendations for recognized manifestations of Lyme disease in children. However, major randomized trials examining persistent symptoms and additional antibiotic treatment enrolled adults rather than children.

This leaves an important evidence gap. Clinicians must often consider findings from adult trials when caring for children whose development, medication risks, school functioning, and family circumstances may differ substantially.

Quick Answer: What Is the Pediatric Lyme Treatment Evidence Gap?

Children have been largely excluded from major clinical trials evaluating additional antibiotic treatment for persistent symptoms following initial Lyme disease therapy. Consequently, these trials do not directly determine whether their benefits, limitations, and risks apply to pediatric patients. More pediatric research is needed to guide treatment decisions when children remain ill.

Initial Treatment and Persistent Symptoms Are Different Questions

It is important to distinguish between the initial treatment of recognized Lyme disease manifestations and decisions involving persistent symptoms.

Existing guidelines include pediatric antibiotic choices, weight-based dosing, and recommended treatment durations for manifestations such as erythema migrans, facial nerve palsy, Lyme meningitis, carditis, and Lyme arthritis.

The evidence becomes less direct when a child continues to experience fatigue, pain, cognitive difficulties, sleep disruption, or functional limitations after completing initial treatment. The major randomized retreatment trials frequently cited in discussions of persistent Lyme disease did not include children.

Why Children Need Their Own Evidence

Children are not simply smaller adults. Age, weight, medication tolerability, development, communication skills, and the demands of school and family life can all influence clinical decisions.

Persistent symptoms may also be expressed differently in children. Instead of describing “brain fog,” fatigue, or pain precisely, a child may demonstrate changes such as:

• Declining school performance or difficulty completing assignments
• Reduced attention, memory, or processing speed
• Irritability, emotional changes, or withdrawal from usual activities
• Sleep disturbance or difficulty waking for school
• Reduced physical stamina or inability to participate in sports
• Dizziness, imbalance, or an increased risk of falls
• Loss of independence in previously manageable daily activities

These changes are not specific to Lyme disease and may have several possible explanations. Nevertheless, they are clinically important and should not be dismissed simply because a child cannot describe symptoms in the same way an adult can.

Children Were Excluded From Major Lyme Retreatment Trials

Four frequently cited trials examined additional antibiotic treatment in adults with persistent symptoms attributed to or following Lyme disease:

• Klempner trials: Two controlled trials published in 2001 evaluated 90 days of intravenous and oral antibiotic treatment in adults with persistent symptoms and a history of Lyme disease.
• STOP-LD trial: This 2003 trial examined intravenous ceftriaxone in adults with severe persistent fatigue following Lyme disease treatment.
• Fallon trial: This trial evaluated repeated intravenous ceftriaxone in adults with persistent cognitive symptoms described as post-treatment Lyme encephalopathy.
• PLEASE trial: This European trial compared longer-term antibiotic regimens in adults with persistent symptoms attributed to Lyme disease.

None of these trials included children. Their findings therefore do not directly answer how additional treatment affects pediatric patients with persistent symptoms following initial Lyme disease therapy.

The trials also differed in their eligibility criteria, treatment regimens, outcome measures, and patient populations. Some reported improvement in selected outcomes, while others did not demonstrate sustained benefit on their primary measures. These differences have contributed to continuing disagreement about how the results should be interpreted.

What Adult Retreatment Trials Cannot Tell Us About Children

Adult studies can inform clinical discussions, but they cannot fully answer pediatric questions such as:

• Do children with persistent symptoms have the same treatment responses as adults?
• Are the medication risks and benefits comparable across different pediatric age groups?
• Which symptoms and functional outcomes should pediatric trials measure?
• How should improvement in school attendance, cognition, sleep, mood, and physical activity be evaluated?
• Are there pediatric subgroups that respond differently to additional treatment?
• How should clinicians distinguish ongoing manifestations of Lyme disease from treatment effects, another tick-borne infection, or an unrelated condition?

Until these questions are studied directly, recommendations based largely on adult retreatment trials will have limited certainty when applied to children.

Guidelines and the Pediatric Evidence Gap

The 2020 IDSA/AAN/ACR guideline includes recommendations for treating recognized manifestations of Lyme disease in both adults and children. It recommends against additional antibiotic treatment for persistent nonspecific symptoms when there is no objective evidence of reinfection or treatment failure.

The ILADS guidelines—on which I served as an author in 2004 and 2014—emphasize individualized clinical judgment and shared decision-making when patients remain ill after initial treatment. This includes considering the severity of the illness, the patient’s response to previous treatment, alternative diagnoses, treatment risks, and the patient’s values and circumstances.

Neither guideline position changes the underlying research limitation: randomized pediatric retreatment trials have not established how children with persistent symptoms respond to additional antibiotic treatment.

Coinfections and Alternative Explanations Must Be Considered

Persistent symptoms following Lyme disease treatment should not automatically be attributed to one cause. A careful evaluation may need to consider:

• Incomplete resolution of the original illness
• Reinfection following another tick bite
• Possible tick-borne coinfections when clinically and epidemiologically appropriate
• Medication side effects
• Sleep, nutritional, endocrine, autoimmune, neurologic, or psychiatric conditions
• Deconditioning or autonomic dysfunction
• The educational and emotional consequences of prolonged illness

Babesia, Anaplasma, Ehrlichia, and other infections require their own diagnostic and treatment approaches. Bartonella may also enter the differential diagnosis in selected clinical circumstances, although its relationship to tick transmission and persistent Lyme disease remains debated.

Additional antibiotics should therefore not be treated as an automatic response to every persistent symptom. At the same time, continuing symptoms deserve a thoughtful clinical assessment rather than dismissal.

Why Pediatric Outcomes Must Include Daily Function

A laboratory result or symptom questionnaire may not fully capture the effect of persistent illness on a child. Pediatric research should also evaluate:

• School attendance
• Academic performance
• Attention, memory, and processing speed
• Sleep quality
• Physical activity and exercise tolerance
• Mood and behavior
• Social participation
• Family functioning

Persistent illness during childhood can interfere with education, development, friendships, and growing independence. These outcomes should be measured directly in future pediatric studies.

Clinical Takeaways

Until research expands, clinicians and families should:

• Recognize that children were excluded from the major Lyme retreatment trials.
• Avoid assuming that adult findings apply perfectly to pediatric patients.
• Evaluate persistent symptoms carefully rather than assigning them automatically to Lyme disease or dismissing them as nonspecific.
• Consider alternative diagnoses, reinfection, coinfections, medication effects, and other contributing conditions.
• Balance the possible benefits and risks of any treatment decision.
• Monitor school performance, cognition, sleep, mood, physical function, and quality of life.
• Include parents and children in shared decision-making whenever developmentally appropriate.

The Bottom Line

Published guidelines provide treatment recommendations for recognized manifestations of pediatric Lyme disease. The larger uncertainty involves children who remain ill after initial therapy.

Major randomized trials evaluating additional antibiotic treatment for persistent Lyme disease symptoms enrolled adults, not children. Their findings can contribute to clinical discussions, but they cannot directly establish what is most effective or safest for pediatric patients.

Both undertreatment and unnecessary treatment carry risks. Until pediatric trials address persistent symptoms and retreatment directly, care must rely on careful clinical judgment, ongoing monitoring, shared decision-making, and attention to each child’s medical and functional needs.

This article is for educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment.

Related Articles

• Only a Minority of Children With Lyme Disease Recall a Tick Bite
• Study Shows Doctors Can Misdiagnose Lyme Disease
• Why Lyme Disease Treatment Is Not One-Size-Fits-All
• Pediatric Lyme Disease: Symptoms, Diagnosis, and Challenges

References

Klempner, M. S., Hu, L. T., Evans, J., et al. (2001). Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. The New England Journal of Medicine, 345(2), 85–92.

Krupp, L. B., Hyman, L. G., Grimson, R., et al. (2003). Study and treatment of post Lyme disease (STOP-LD): A randomized double-masked clinical trial. Neurology, 60(12), 1923–1930.

Fallon, B. A., Keilp, J. G., Corbera, K. M., et al. (2008). A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology, 70(13), 992–1003.

Berende, A., ter Hofstede, H. J. M., Vos, F. J., et al. (2016). Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. The New England Journal of Medicine, 374(13), 1209–1220. PubMed

Cameron, D. J., Johnson, L. B., & Maloney, E. L. (2014). Evidence assessments and guideline recommendations in Lyme disease: The clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Review of Anti-infective Therapy, 12(9), 1103–1135.

Lantos, P. M., Rumbaugh, J., Bockenstedt, L. K., et al. (2021). Clinical practice guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Clinical Infectious Diseases, 72(1), e1–e48.

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention